New drug MDI-2517 put to the test in first human safety trial
NCT ID NCT07220889
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety of a new drug called MDI-2517 in 32 healthy adults aged 18 to 55. Participants received either a single or multiple doses of the drug or a placebo. Researchers monitored side effects, lab results, vital signs, and how the drug moves through the body. The study is complete, but it only looked at safety and drug levels, not whether the drug treats any condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MDI-2517
What could go wrong
This is a very early Phase 1 trial with only 32 healthy people, so it cannot tell us if the drug works for any disease. The main goal is just safety, and many drugs fail at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY AFTER ORAL INTAKE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
1951 NW 7th Avenue, Suite 180
Miami, Florida, 33136, United States